Last reviewed · How we verify
NCT02376933
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
NA trial testing Vertebroplasty in Metastatic Cancers in 11 participants. Terminated before completion.
10 August 2016
Quick facts
| Lead sponsor | University of Arizona |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 20 August 2013 |
| Primary completion | 10 August 2016 |
| Estimated completion | 7 April 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Vertebroplasty
- Radiotherapy — full drug profile →
Conditions studied
- Metastatic Cancers — all drugs for Metastatic Cancers →
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Vertebral Fracture — all drugs for Vertebral Fracture →
Sponsor
University of Arizona
Who can join
18 and older, any sex, with Metastatic Cancers or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Serious adverse events (2 terms)
| Reaction | System | Vertebroplasty With Radiot… |
|---|---|---|
| Gastrointestinal - other | Gastrointestinal disorders | — |
| Back pain | Musculoskeletal and connective tissue disorders | — |
Other adverse events (14 terms — click to expand)
| Reaction | System | Vertebroplasty With Radiot… |
|---|---|---|
| Back pain | Musculoskeletal and connective tissue disorders | — |
| Pain | General disorders | — |
| Fatigue | General disorders | — |
| Vomiting | Gastrointestinal disorders | — |
| Bone pain | Musculoskeletal and connective tissue disorders | — |
| Constipation | Gastrointestinal disorders | — |
| Cough | Respiratory, thoracic and mediastinal disorders | — |
| Dehydration | Metabolism and nutrition disorders | — |
| Diarrhea | Gastrointestinal disorders | — |
| Dry skin | Skin and subcutaneous tissue disorders | — |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | — |
| Fall | Injury, poisoning and procedural complications | — |
| Flu-like syndrome | General disorders | — |
| Nausea | Gastrointestinal disorders | — |
Most-reported serious reactions: Gastrointestinal - other, Back pain.
Data from ClinicalTrials.gov NCT02376933 adverse events section.
Sponsor's own description
Vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02376933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vertebroplasty
Trials testing the same drug.
- NCT06670404 — Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures · recruiting
- NCT06141187 — Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy. · NA · recruiting
- NCT05317026 — Increased Early Pain Relief by Adding Vertebroplasty to SBRT · NA · recruiting
- NCT05178472 — Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) · NA · recruiting
- NCT04533217 — Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. · NA · recruiting
Other recruiting trials for Metastatic Cancers
Currently open trials in the same condition.
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06929910 — Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing. · recruiting
- NCT06678659 — A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer · Phase 1, PHASE2 · recruiting
- NCT06085716 — Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers · Phase 2, PHASE3 · recruiting
- NCT02304809 — Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations · Phase 2 · active not recruiting
Other University of Arizona trials
Trials by the same sponsor.
- NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
- NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
- NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
- NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
- NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02376933 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arizona
- Last refreshed: 7 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02376933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing